Results 71 to 80 of about 54,977 (304)

SMC3 epigenetic silencing regulates Rab27a expression and drives pancreatic cancer progression

Journal of Translational Medicine, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) is expected to soon surpass colorectal cancer as a leading cause of cancer mortality in both males and females in the US, only lagging behind lung cancer.
Nuno Bastos, Stéphanie A. Castaldo, Bárbara Adem, José C. Machado, Carlos A. Melo, Sonia A. Melo   +5 more
doaj   +1 more source

AACR PDAC Meeting 2023 Bibliography

, 2023
AACR PDAC Meeting 2023 BibliographyTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Chen, J (via Mendeley Data)
core   +1 more source

WT1‐Targeted Oral Bifidobacterium longum Vaccine Enhances Checkpoint Blockade Efficacy in Pancreatic Cancer

Advanced Science, EarlyView.
Oral WT1‐targeted Bifidobacterium longum vaccine promotes WT1‐associated cellular immunity and enhances anti‐PD‐1/anti‐CTLA‐4 efficacy in pancreatic cancer. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immune checkpoint inhibitors (ICI) due to its profoundly immunosuppressive tumor microenvironment.
Taiki Yamazaki, Aori Minami, Misako Hirota, Mirei Hirano, Ryota Sato, Atsuki Honma, Hideto Ueki, Toshiro Shirakawa   +7 more
wiley   +1 more source

Advances in Early Detection of Pancreatic Cancer

Diagnostics, 2019
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease. PDAC is the fourth leading cause of death in the United States and Japan based on epidemiological data. Early detection of PDAC is very important to improve the prognosis of PDAC.
Atsushi Kanno, Atsushi Masamune, Keiji Hanada, Masataka Kikuyama, Masayuki Kitano   +4 more
doaj   +1 more source

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao, Yu He, Wenhao Li, Bo Gong, Han Lin, Jianlin Shi, Yuan Yong, Wencheng Wu   +7 more
wiley   +1 more source

Soluble stroma‐related biomarkers of pancreatic cancer

EMBO Molecular Medicine, 2018
The clinical management of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of reliable biomarkers. This study investigated the value of soluble stroma‐related molecules as PDAC biomarkers.
Andrea Resovi, Maria Rosa Bani, Luca Porcu, Alessia Anastasia, Lucia Minoli, Paola Allavena, Paola Cappello, Francesco Novelli, Aldo Scarpa, Eugenio Morandi, Anna Falanga, Valter Torri, Giulia Taraboletti, Dorina Belotti, Raffaella Giavazzi   +14 more
doaj   +1 more source

The expression of SPRR1A in PDAC.

, 2022
(a) The comparison of the SPRR1A expression (TPM) between normal pancreas tissue (n = 245) and pancreatic cancer (n = 177). The SPRR1A expression was elevated in 89 of 177 cases. ****p t-test. The dotted line shows TPM 9.34, the second-highest expression
Keiichiro Uehara (3400055), Takashi Aoi (595203), Hirochika Toyama (11446949), Kohei Yamakawa (3523370), Yuzo Kodama (5718695), Takumi Fukumoto (6496868), Michiyo Koyanagi-Aoi (9456213), Atsuhiro Masuda (4857223), Hiroaki Yanagimoto (626327)   +8 more
core   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Label-Free Quantitative Proteomics Unravels Carboxypeptidases as the Novel Biomarker in Pancreatic Ductal Adenocarcinoma

Translational Oncology, 2018
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a high mortality rate and poor prognosis. However, little is known concerning the molecular mechanism of PDAC at the proteomics level. Here we report a proteomics analysis of
Yang Song, Qing Wang, Desheng Wang, Junqiang Li, Jing Yang, Hong Li, Xiang Wang, Xuerong Jin, Ruirui Jing, Jing-Hua Yang, Haichuan Su   +10 more
doaj   +1 more source

Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. [PDF]

Cancer Sci
Schematic overview of a cell‐of‐origin‐based classification of pancreatic ductal adenocarcinoma (PDAC), highlighting distinct biological features and therapeutic implications of Acinar‐ and Ductal‐subtypes. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor clinical ...
Kikuchi T, Ako S, Kato H, Kinugasa H, Uchida M, Oda T, Hirai R, Matsumi A, Miyamoto K, Terasawa H, Fujii Y, Uchida D, Matsumoto K, Tsutsumi K, Horiguchi S, Yasui K, Fuji T, Takagi K, Kato H, Honda T, Otsuka F, Otsuka M.   +21 more
europepmc   +2 more sources